Skip to main content

Ibane Abasolo Olaortua

I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Biologist
Bioquímica
Cross-departmental services

Ibane Abasolo Olaortua

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Biologist
Bioquímica
Cross-departmental services

I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.

I graduated in Biochemistry and Biology at the University of Navarra. During my doctorate in the laboratories of Dr. Alfonso Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern University, Chicago, USA), I studied the role of a peptide hormone, adrenomedullin, in cancer. Later, I continued my postdoctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where I acquired extensive experience in experimental mouse models, from the generation of transgenic models to their molecular characterization, an experience that I completed with a specialization in molecular imaging techniques at the IAT-PRBB.
Since 2007, I have been working at Vall d'Hebron, where I started as a post-doctoral researcher and head of the technology platform called Functional Validation & Preclinical Research (FVPR)-U20 ICTS. Since 2021 I am also the leader of the Drug Delivery & Targeting group at VHIR and at the CIBER for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).
My research, and that of my group, seeks to improve the treatment of different diseases through the use of nanoparticles and hydrogels. These systems are specifically designed to protect the therapeutic agent and cause it to be released where and when it is needed. Noteworthy, we work at all steps of the preclinical development, from the design of the nanomaterial, to its synthesis, characterization and testing in experimental models of the disease.
I am currently leading two European projects (SafeNMT and Mimic-key) and two Spanish projects (PI21/00930 and NanoDireCT), focused on the treatment of cancer (breast, pancreas and prostate) and lysosomal storage diseases (Fabry, Sanfilippo and pycnodysostosis).

Projects

Activación de vías dependientes del oncogen BRAF en la tumorogénesis y metástasis del cáncer colorectal en modelos in vivo

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua
Funding agency: Instituto de Salud Carlos III
Funding: 219252
Reference: PI080771
Duration: 01/01/2009 - 30/06/2012

Direccionament i Alliberament Farmacològic

IP: Simon Schwartz Navarro
Collaborators: Manuel López Cano, Ibane Abasolo Olaortua, Laura García Latorre, Manuel Armengol Carrasco, Eloy Espín Basany
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 43680
Reference: 2009 SGR 758
Duration: 01/01/2010 - 30/04/2014

Integrated approach for the improved microbial production of high quality therapeutic enzymes (IMAPPROT)

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 164000
Reference: EUI2008-03741
Duration: 01/03/2009 - 30/06/2012

Ministerio de Ciencia

CIBER: Bioingenieria, biomateriales y nanomedicina

IP: -
Collaborators: Ibane Abasolo Olaortua, Manuel López Cano, Jaume Alijotas Reig, Francesc Miro Mur, Eloy Espín Basany, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua
Funding agency: CIBER Bioing., Biomateriales y Nanomedicina , BBN
Funding: 480000
Reference: CB06/01/0012
Duration: 01/01/2007 - 31/12/2010

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Alfonso Biarnes Suñe

Alfonso Biarnes Suñe

Reconstructive Surgery of the Locomotor System
Read more
Isaac Manjon Fernández

Isaac Manjon Fernández

Research technician
Microbiome Research
Read more
Natalia Rey Viñets

Natalia Rey Viñets

Research technician
Genetics Medicine
Read more
Juan Duque Yehail

Juan Duque Yehail

Predoctoral researcher
Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.